When is the Bio-Rad Laboratories (BIIB) Earnings Report?

If you’re looking for the date of the Bio-Rad Laboratories (BIIB) quarterly earnings release, then you’ve come to the right place. We’ll walk you through the key points to keep an eye out for on Bio.B’s earnings report, including its analyst comments and financial data. Then, we’ll discuss how investors can use the news to their advantage.

Bio-Rad Laboratories (BIIB) quarterly earnings report

In its most recent quarterly earnings report, Bio-Rad Laboratories Inc. reported net sales of $732.8 million for the fourth quarter of 2021. This was down 7.2 percent from the fourth quarter of 2020 and 6.9% from the prior-year quarter. The company’s gross margin was 54.7 percent, down from 58.3 percent in the prior-year period. The company’s operating profit was $74.4 million for the quarter.

The company’s revenue growth was better than expected, fueled by robust COVID-19 testing demand and the company’s emergency use authorization from the FDA. Revenues increased in both operating segments and across all major geographic regions, despite a slight decline in clinic visits and non-critical hospital visits. Bio-Rad has withdrawn its full-year guidance, which reflects its declining outlook for the second quarter.

Bio-Rad Laboratories (BIIB) earnings call

During the Bio-Rad Laboratories (NASDAQ:BIIB) earnings call, CEO Steven Spangler highlighted the company’s continued growth and diversification into new areas. While its market for blood typing instruments remains stagnant, Bio-Rad is positioning itself to take advantage of the growing market for cell and tissue analysis. In addition to its current portfolio of instruments, the company plans to expand into new areas, including safe transfusion.

While the company’s top-line revenue rose by 1% in Q120, operating expenses declined by 23%, and operating income increased to $230m from -$103m last year, the company’s unrealised gains are nearly $2.0 billion over the next three years. The stock is set for another blockbuster quarter, and the company has a history of producing such earnings.

As for the company’s future, management said it remains committed to investing in research and development. Its Aduhelm Alzheimer’s disease drug, a breakthrough in the field, is now FDA-approved. Clearly, it will take continued investment to develop new treatments for Alzheimer’s disease. In the meantime, the company plans to continue investing in its current pipeline of products and services, including new diagnostics.

Bio-Rad Laboratories (BIIB) earnings release

In its latest earnings release, Bio-Rad outlined its plans to expand its business beyond blood typing. Bio-Rad believes that it is the second-largest blood typing supplier in the world, having placed more than 4,000 automated systems in labs around the world. It also outlined plans to expand its product portfolio beyond blood typing to cover safe transfusions. In August 2018, Bio-Rad paid $60 million to acquire Exact Diagnostics, a biotechnology company that specializes in quality controls and assay verification panels. The acquisition boosted Bio-Rad’s market penetration.

In Q120, Bio-Rad’s two core businesses posted so-so results, but still offer substantial future value. In Q120, the company reported net profits of $74 million. In 2019, Bio-Rad expects to realise unrealised gains of $2.0 billion on its Sartorius biotechnology product. Sartorius has gained 37% since Q1 of this year, and it’s poised for another blockbuster quarter.

Bio-Rad Laboratories (BIIB) earnings release date

The company’s Life Sciences division, which provides products for research and diagnostic purposes, accounted for more than 40% of revenue in Q120. It estimates the IVD market to be worth at least $12 billion, and has placed more than 4,000 automated systems in laboratory environments. The company sells reagents and test kits to make sure that every sample yields a reproducible test result. This approach generates recurring revenues, and the company has introduced several new products, such as a line of flow cytometry.

While Bio-Rad’s two core businesses have been delivering solid results in recent quarters, there are a few points to note. First, investors should be aware that Bio-Rad has not yet turned a profit on its Sartorius investments, and will therefore be relying on its more reliable and consistent core operations to make up for the loss. In addition, Bio-Rad will have to deal with the uncertainty associated with the Sartorius acquisition, which will reduce its margins and result in lower operating income.

Investors should also be aware of Sartorius’ upcoming earnings release date. The upcoming earnings date is based on an algorithm derived from the company’s historical reporting dates. This information will be revised once the company reports its actual date. Bio-Rad Laboratories (BIIB) will likely report a low-quality earnings report when the company’s stock price decreases by 1% in the third quarter.